-
Abstract Number: 2894
CD6-ALCAM Signaling Is Upregulated in Kidneys with Lupus Nephritis and Is Associated with Disease Activity
-
Abstract Number: 2895
Complement Protein CL-K1 at High Concentrations Protects Against the Development of Lupus Nephritis
-
Abstract Number: 2896
The Role of Alterations in the Splicing Machinery in the Pathogenesis of Lupus: Does It Impact Lupus Nephritis?
-
Abstract Number: 2897
Increased CD69+ Tissue-resident Memory T (TRM) Cells and STAT3 Expression in Cutaneous Lupus Erythematosus Patients Recalcitrant to Antimalarials
-
Abstract Number: 2898
Evaluation of the Transcriptome of Non-Lesional, Non-Sun Exposed Skin in Patients with Lupus Nephritis
-
Abstract Number: 2899
Transcriptomic Meta-analysis of Lupus Affected Tissues Reveals Shared Immune, Metabolic, and Biochemical Dysregulation
-
Abstract Number: 2900
Interferon Signature Predicts Response to Tofacitinib in Haploinsufficiency of A20
-
Abstract Number: 2901
Anakinra Treatment in Patients with Familial Mediterranean Fever: A Single-center Experience
-
Abstract Number: 2902
The Use and Safety of Rituximab in Connective Tissue Disease Associated Interstitial Lung Disease
-
Abstract Number: 2903
Cryopyrin-Associated Periodic Syndrome Treated with Canakinumab – Long-Term Follow-up Data Documents Sustained Safety and Remission
-
Abstract Number: 2904
Rituximab as Rescue Therapy in Treatment-Refractory CTD-ILD
-
Abstract Number: 2905
Rilonacept in Recurrent Pericarditis: Efficacy and Safety Data from an Ongoing Phase 2 Pilot Clinical Trial
-
Abstract Number: 2906
DMARD-free Remission in Established Rheumatoid Arthritis: 2 Year Results of the TARA Trial
-
Abstract Number: 2907
Clinical and Functional Outcomes Among Rheumatoid Arthritis Patients Switching Between JAK1-Selective Inhibitor Upadacitinib and Adalimumab Following Insufficient Response
-
Abstract Number: 2908
Remission in Patients with Rheumatoid Arthritis Receiving Triple Therapy Compared to Biological Therapy – A Swedish Nationwide Register Study
2019 ACR/ARP Annual Meeting
November 8-13, 2019. Atlanta, GA.